A PharmD candidate reflects on the small, evidence-backed daily habits that helped her thrive—not just survive—through pharmacy school's most demanding years.
|Articles|January 15, 2019
- January 2019 Vaccine-Preventable Disease
- Volume 85
- Issue 1
Can You Read These Rxs? (January 2019)
Can you figure out what these prescriptions say?
Advertisement
Rx 1: Shiela Narayan, RPh; Christina Tucker, CPhT; and Perry Chu, RPh, of Sav-on Pharmacy in Las Vegas could not read everything on this prescription. Can you read it?
Rx 2: Pharmacist Beth Willie, PharmD, of County Market Pharmacy in Springfield, Illinois, wrote, “The script says Gabapentin 200 mg PO QHS, but I was unsure what followed the directions.” Can you decipher the last part?
Answers:
Rx 1: Motrin 600 mg PO #40 q 8 prn; Soma 350 mg PO qhs prn #30
Rx 2: A 14-day supply
Articles in this issue
over 7 years ago
Organize Marketing to Increase Pharmacy Cash Flowover 7 years ago
Can Pharmacists Take Legal Action After Being Fired?over 7 years ago
New Opioid Approval Creates Controversyover 7 years ago
Patients Are Increasingly at Risk for Insulin-Drug Interactionsalmost 8 years ago
Managing Patients With Type 2 Diabetes Poses Challengesalmost 8 years ago
Pharmacists Need to Understand Law Related to Controlled Substancesalmost 8 years ago
Minimize the Likelihood of Vaccine-Related Adverse ReactionsAdvertisement
Related to this article
Understanding local health care priorities is essential to developing meaningful solutions.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Two recent graduates share strategies for standing out in the competitive fellowship application process.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
3
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
4
Safety and Monitoring – Hypophosphatemia, Infusion Reactions, and Adverse-Event Management
5